Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy

Yogita Ghodke Puranik, Angela K. Birnbaum, Susan E. Marino, Ghada Ahmed, James C. Cloyd, Rory P. Remmel, Ilo E. Leppik, Jatinder K. Lamba

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Aim: The aim of this study was to evaluate the association of genetic variants in the major genes involved in carbamazepine (CBZ) metabolism and transport with its pharmacokinetics in epilepsy patients. Materials & methods: Twenty-five SNPs within seven CBZ pathway genes, namely CYP3A4, CYP3A5, EPHX1, NR1I2, UGT2B7, ABCB1 and ABCC2, were analyzed for association with CBZ pharmacokinetics in 90 epilepsy patients. Results: The CYP3A4*1B SNP was significantly associated with CBZ clearance. Significant association of EPHX1 SNPs was observed with greater carbamazepine-10,11-trans dihydrodiol: carbamazepine 10-11 epoxide ratios. Among drug transporters, ABCB1 and ABCC2 SNPs were significantly associated with altered CBZ clearance. Conclusion: SNPs within CBZ pathway genes contribute to interpatient variation in CBZ pharmacokinetics and might contribute to pharmacoresistant epilepsy. Although our results need further clinical validation in a larger patient cohort, they indicate that genetic variation in CBZ pathway genes could influence its pharmacokinetics, and hence would have clinical significance. Original submitted 2 August 2012; Revision submitted 16 October 201.

Original languageEnglish (US)
Pages (from-to)35-45
Number of pages11
JournalPharmacogenomics
Volume14
Issue number1
DOIs
StatePublished - Jan 1 2013

Fingerprint

Carbamazepine
Epilepsy
Pharmacokinetics
Single Nucleotide Polymorphism
Cytochrome P-450 CYP3A
Genes
Pharmaceutical Preparations

Keywords

  • ABCB1
  • ABCC2
  • CYP3A4
  • EPHX1
  • UGT2B7
  • carbamazepine
  • pharmacogenomics
  • pharmacokinetics

Cite this

@article{8128dd41b10044e6bf16bbe4f3385185,
title = "Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy",
abstract = "Aim: The aim of this study was to evaluate the association of genetic variants in the major genes involved in carbamazepine (CBZ) metabolism and transport with its pharmacokinetics in epilepsy patients. Materials & methods: Twenty-five SNPs within seven CBZ pathway genes, namely CYP3A4, CYP3A5, EPHX1, NR1I2, UGT2B7, ABCB1 and ABCC2, were analyzed for association with CBZ pharmacokinetics in 90 epilepsy patients. Results: The CYP3A4*1B SNP was significantly associated with CBZ clearance. Significant association of EPHX1 SNPs was observed with greater carbamazepine-10,11-trans dihydrodiol: carbamazepine 10-11 epoxide ratios. Among drug transporters, ABCB1 and ABCC2 SNPs were significantly associated with altered CBZ clearance. Conclusion: SNPs within CBZ pathway genes contribute to interpatient variation in CBZ pharmacokinetics and might contribute to pharmacoresistant epilepsy. Although our results need further clinical validation in a larger patient cohort, they indicate that genetic variation in CBZ pathway genes could influence its pharmacokinetics, and hence would have clinical significance. Original submitted 2 August 2012; Revision submitted 16 October 201.",
keywords = "ABCB1, ABCC2, CYP3A4, EPHX1, UGT2B7, carbamazepine, pharmacogenomics, pharmacokinetics",
author = "Puranik, {Yogita Ghodke} and Birnbaum, {Angela K.} and Marino, {Susan E.} and Ghada Ahmed and Cloyd, {James C.} and Remmel, {Rory P.} and Leppik, {Ilo E.} and Lamba, {Jatinder K.}",
year = "2013",
month = "1",
day = "1",
doi = "10.2217/pgs.12.180",
language = "English (US)",
volume = "14",
pages = "35--45",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy

AU - Puranik, Yogita Ghodke

AU - Birnbaum, Angela K.

AU - Marino, Susan E.

AU - Ahmed, Ghada

AU - Cloyd, James C.

AU - Remmel, Rory P.

AU - Leppik, Ilo E.

AU - Lamba, Jatinder K.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Aim: The aim of this study was to evaluate the association of genetic variants in the major genes involved in carbamazepine (CBZ) metabolism and transport with its pharmacokinetics in epilepsy patients. Materials & methods: Twenty-five SNPs within seven CBZ pathway genes, namely CYP3A4, CYP3A5, EPHX1, NR1I2, UGT2B7, ABCB1 and ABCC2, were analyzed for association with CBZ pharmacokinetics in 90 epilepsy patients. Results: The CYP3A4*1B SNP was significantly associated with CBZ clearance. Significant association of EPHX1 SNPs was observed with greater carbamazepine-10,11-trans dihydrodiol: carbamazepine 10-11 epoxide ratios. Among drug transporters, ABCB1 and ABCC2 SNPs were significantly associated with altered CBZ clearance. Conclusion: SNPs within CBZ pathway genes contribute to interpatient variation in CBZ pharmacokinetics and might contribute to pharmacoresistant epilepsy. Although our results need further clinical validation in a larger patient cohort, they indicate that genetic variation in CBZ pathway genes could influence its pharmacokinetics, and hence would have clinical significance. Original submitted 2 August 2012; Revision submitted 16 October 201.

AB - Aim: The aim of this study was to evaluate the association of genetic variants in the major genes involved in carbamazepine (CBZ) metabolism and transport with its pharmacokinetics in epilepsy patients. Materials & methods: Twenty-five SNPs within seven CBZ pathway genes, namely CYP3A4, CYP3A5, EPHX1, NR1I2, UGT2B7, ABCB1 and ABCC2, were analyzed for association with CBZ pharmacokinetics in 90 epilepsy patients. Results: The CYP3A4*1B SNP was significantly associated with CBZ clearance. Significant association of EPHX1 SNPs was observed with greater carbamazepine-10,11-trans dihydrodiol: carbamazepine 10-11 epoxide ratios. Among drug transporters, ABCB1 and ABCC2 SNPs were significantly associated with altered CBZ clearance. Conclusion: SNPs within CBZ pathway genes contribute to interpatient variation in CBZ pharmacokinetics and might contribute to pharmacoresistant epilepsy. Although our results need further clinical validation in a larger patient cohort, they indicate that genetic variation in CBZ pathway genes could influence its pharmacokinetics, and hence would have clinical significance. Original submitted 2 August 2012; Revision submitted 16 October 201.

KW - ABCB1

KW - ABCC2

KW - CYP3A4

KW - EPHX1

KW - UGT2B7

KW - carbamazepine

KW - pharmacogenomics

KW - pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84871405336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871405336&partnerID=8YFLogxK

U2 - 10.2217/pgs.12.180

DO - 10.2217/pgs.12.180

M3 - Article

C2 - 23252947

AN - SCOPUS:84871405336

VL - 14

SP - 35

EP - 45

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 1

ER -